Laura Montour

Jul 22, 2024 | nationalgeographic.es | Laura Montour

Cada vez hay más pruebas de que medicamentos como Ozempic y Mounjaro, desarrollados originalmente para la diabetes y aprobados después para la obesidad, tienen beneficios que van más allá de estas afecciones. Entre ellos figuran la reducción del riesgo de diez tipos de cáncer, protección contra enfermedades cardiacas y renales, y reducción de la inflamación sistémica, según investigaciones publicadas recientemente.

Jul 19, 2024 | nationalgeographic.com | Laura Montour

More evidence suggests that medications such as Ozempic and Mounjaro, originally developed for diabetes and then approved for obesity, have benefits that go beyond these conditions. Those include lower risk of 10 cancers, protection against heart and kidney diseases, and reduction in systemic inflammation, according to recently published research.

Dec 30, 2023 | bmjopen.bmj.com | Nicole Ehrhardt |Brian Cedeno |Laura Montour |Ka'imi Sinclair

Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. DIABETES & ENDOCRINOLOGYGENERAL MEDICINE (see Internal Medicine)Health EquityTraining in digital literacy is an integral part of the study.